NIH Article Blames Heart Attacks Post Vaccination on ‘Anti-Vaxxers’ Stressing People to Death

Just when you thought the public health tyrants couldn’t get any more ridiculous, they find a way to amaze us.

In an article published by Biomedicine (Taipei), vaccine adverse effects are blamed on fear mongering and misinformation by ‘anti-vaxxers.’

The publication, found in the NIH National Library of Medicine, claims that ‘stress’ perpetuated by anti-vaxxers causes more deaths and injuries to vaccines.

Read More

NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid Responding to reports of patients relapsing after completing a five-day course of Paxlovid, Pfizer CEO Albert Bourla suggested patients just take more, prompting a rebuke from a U.S. Food and Drug Administration official.

Miss a day, miss a lot. Subscribe to The Defender’s Top News of the DayIt’s free.

National Institutes of Health (NIH) researchers said they will investigate how often and why coronavirus levels rebound in some patients who complete a five-day course of Pfizer’s COVID-19 antiviral pill, Paxlovid.

“It is a priority,” Clifford Lane, deputy director for clinical research at the National Institute of Allergy and Infectious Diseases, told Bloomberg. It’s “a pretty urgent thing for us to get a handle on.”

Lane said the agency is discussing with scientists at the Centers for Disease Control and Prevention possible epidemiological and clinical studies to examine post-Paxlovid rebound.

In response to reports of patients relapsing after taking Paxlovid, Pfizer CEO Albert Bourla on Tuesday suggested they take more of the treatment, contrary to the established protocol.

Bourla’s comment prompted a U.S. Food and Drug Administration (FDA) official on Wednesday to contradict Bourla, FiercePharma reported.

John Farley, M.D., director of the Office of Infectious Diseases, in the FDA Updates on Paxlovid for Health Care Providers wrote:

“There is no evidence of benefit at this time for a longer course of treatment (e.g., 10 days rather than the 5 days recommended in the Provider Fact Sheet for Paxlovid) or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course.”

Read More

%%footer%%